

RECEIVED
CENTRAL FAX CENTER

DEC 09 2005

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. QMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/801185-Conf. #1672
		Filing Date	March 7, 2001
		First Named Inventor	Jochen G. SALFELD
		Art Unit	1844
		Examiner Name	D. A. Saunders
Sheet 1 of 2	Attorney Docket Number	BBI-43CPUSCNRCE	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinetic Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office of the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of documents by the appropriate symbols as indicated on the documents under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T*
	C1	Abraham, Edward, et al., "Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients with Sepsis Syndrome," JAMA, Vol. 273(12):934-941 (1995)				
	C2	Boekstegers, P., et al., "Repeated administration of a E(ab) ₂ fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels," Shock, Vol. 1(4):237-245 (1994) (abstract from Pub Med)				
	C3	Brekke, Ole Henrik, et al., "Therapeutic antibodies for human diseases at the dawn of the twenty-first century," Nature Reviews/Drug Discovery, Vol. 2:52-62 (2003)				
	C4	Cohen, Jonathan, et al., "Intercept: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor- α in patients with sepsis," Crit Care Med, Vol. 24(9):1431-1440 (1996)				
	C5	Department of Surgery, University of Toronto Annual Report, July 1, 1998 - June 30, 1999 - found online at http://www.surg.med.utoronto.ca/AnnRep/AR98_99/index.html				
	C6	Feldman, Marc, et al., "Anti-TNF α Therapy of Rheumatoid Arthritis: what Have We Learned?" Annu. Rev. Immunol., Vol. 19:163-196 (2001)				
	C7	Figini, Mariangela, et al., "In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation," J. Mol. Biol., Vol. 239:68-78 (1994)				
	C8	Hawkins, Robert B., et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation," J. Mol. Biol., Vol. 226:889-898 (1992)				
	C9	Holler, E., et al., "Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F)," Blood, Vol. 86(3):890-899 (1995) (abstract from Pub Med)				
	C10	Hoogenboom, Henning R., et al., "Converting rodent into human antibodies by guided selection," Antibody Engineering, Oxford University Press, pp. 169-185 (1996)				
	C11	Jespers, Laurent S., et al., "Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen," BioTechnology, Vol. 12:899-903 (1994)				
Examiner Signature	David A. Saunders				Date Considered	10/6/06

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known Application Number 09/801185-Conf. #1672 Filing Date March 7, 2001 First Named Inventor Jochen G. SALFELD An Uns 1644 Examiner Name D. A. Saunders Attorney/Doctet Number BBH-43CPUSCNRCE	
Sheet	2	of	2

C12	Kempeni, Joachim, "Update on D2E7: a fully human anti-tumor necrosis factor α monoclonal antibody," <i>Ann Rheum Dis</i> , Vol. 58(Suppl. 1):144-145 (2000)
C13	Low, Nigel M., thesis abstract, Cambridge University (1996)
C14	Low, Nigel M., et al., "Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain," <i>J. Mol. Biol.</i> , Vol. 260:359-368 (1996)
C15	Medynski, Dan, "Phage Display: All Dressed Up and Ready to Role," <i>BioTechnology</i> , Vol. 12:1134-1136 (1994)
C16	Nilsson, Björn, "Antibody engineering," <i>Current Opinion in Structural Biology</i> , Vol. 5:450-456 (1995)
C17	Riechmann, L., et al., "Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement," <i>Biochemistry</i> , Vol. 32(34):8848-8855 (1993) (abstract from Pub Med)
C18	Reinhart, K., et al., "Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 186F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study," <i>Crit Care Med</i> , Vol. 24(5):1608 (1996) (abstract from Pub Med)
C19	Senters, L.C., et al., "Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIA core," <i>Analytical Biochemistry</i> , Vol. 299:118-129 (2001)
C20	Thompson, J. et al., "Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity," <i>J. Mol. Biol.</i> , Vol. 256(1):77-88 (1996) (abstract from Pub Med)
C21	Van Der Poll, T., et al., "Effect of postponed treatment with an anti-tumor necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees," <i>Clin Exp Immunol</i> , Vol. 100:21-25 (1995)
C22	Vaughan, Tristan J., et al., "Human antibodies by design," <i>Nature Biotechnology</i> , Vol. 16:533-539 (1998)
C23	Ward, E. Sally, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , Vol. 341(6242):544-546 (1989)
C24	Winter, Greg, et al., "Making antibodies by phage display technology," <i>Annu. Rev. Immunol.</i> , Vol. 12:433-455 (1994)

EXAMINER: If a reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>David A. Saunders</i>	Date Considered	10/16/06
--------------------	--------------------------	-----------------	----------